

Development of a Lead Compound Targeting RNA Methyltransferase METTL3 for Cancer Immunotherapy

K-MEDI hub



ONCOLOGY

Lead

Product Type	Small molecules
Indication	Solid tumor (CRC)
Target	METTL3
MoA(Mechanism of Action)	Inhibition of METTL3 suppresses m6A methylation, leading to activation of CD8+ T cells and modulation of PD-L1 expression, thereby improving the tumor microenvironment and enhancing the antitumor efficacy of combination therapy with the immune checkpoint inhibitor anti-PD-1 antibody.
Competitiveness	- Immuno-oncologic effects by inhibiting M2 macrophage polarization and activating CD8+ T cells. - Antitumor efficacy with minimal toxicity when administered as a monotherapy - Based on the target's immuno-oncology regulatory mechanism, strong antitumor efficacy is anticipated when used in combination with immune checkpoint inhibitors.
Development Stage	Lead
Route of Administration	Oral Administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.